“…The HPLC chromatogram of Re‐risedronate showed one peak at retention time 10.1 min for Re‐risedronate and another beak at 4.2 for ReO 4 − . Technetium complex was washed out with longer retention time than the corresponding rhenium complex, because technetium complex was more hydrophobic than the corresponding rhenium complex, because of the different atomic radii of technetium and rhenium . Similar unmatched retention times have also been observed previously …”
This study aimed to provide an easy method for synthesis of 1-hydroxy-2-(3-pyridyl) ethylidene bisphosphonic acid monosodium (sod. risedronate) with a high yield of 71%. The synthesized risedronate was labeled with technetium-99 m using two different reducing agents (SnCl2 .2H2 O and NaBH4 ) where NaBH4 gave stable complex and higher radiochemical yield more than SnCl2 .2H2 O. The results showed that, the radiochemical purity of (99m) Tc(NaBH4 )-risedronate was 99.2 ± 0.6% and its stability was up to 6 h. Biodistribution study showed high uptake and long retention of (99m) Tc(NaBH4 )-risedronate in bone starting from 15 min (29 ± 2.5% ID/organ) up to 4 h (35.1 ± 3.2 ID/organ) post injection. This research could introduce an easy and effective method for synthesis and labeling of risedrionate and affording a good tracer for bone imaging.
“…The HPLC chromatogram of Re‐risedronate showed one peak at retention time 10.1 min for Re‐risedronate and another beak at 4.2 for ReO 4 − . Technetium complex was washed out with longer retention time than the corresponding rhenium complex, because technetium complex was more hydrophobic than the corresponding rhenium complex, because of the different atomic radii of technetium and rhenium . Similar unmatched retention times have also been observed previously …”
This study aimed to provide an easy method for synthesis of 1-hydroxy-2-(3-pyridyl) ethylidene bisphosphonic acid monosodium (sod. risedronate) with a high yield of 71%. The synthesized risedronate was labeled with technetium-99 m using two different reducing agents (SnCl2 .2H2 O and NaBH4 ) where NaBH4 gave stable complex and higher radiochemical yield more than SnCl2 .2H2 O. The results showed that, the radiochemical purity of (99m) Tc(NaBH4 )-risedronate was 99.2 ± 0.6% and its stability was up to 6 h. Biodistribution study showed high uptake and long retention of (99m) Tc(NaBH4 )-risedronate in bone starting from 15 min (29 ± 2.5% ID/organ) up to 4 h (35.1 ± 3.2 ID/organ) post injection. This research could introduce an easy and effective method for synthesis and labeling of risedrionate and affording a good tracer for bone imaging.
“…The contrastive imaging of [ 99m Tc(CO) 3 (MIBI) 3 ] + and [ 99m Tc(MIBI) 6 ] + in dog showed better myocardium perfusion imaging achieved by the former complex [35]. Moreover, investigation of different synthetic conditions and the inter-transformation of Tc-CO-MIBI complexes was also performed [36]. In order to explain this phenomenon, the mechanism of the water substitution reactions and the carbonyl ligand exchanges by MIBI was proposed and investigated with Gaussian software [37].…”
Section: M Tc Labeled Myocardial Perfusion Imaging Agentsmentioning
The review provides an overview of the current status of radiopharmaceuticals in China for in vivo clinical use and also describes some important advances in the past three decades. Development of the diagnostic and therapeutic radiopharmaceuticals as well as basic research on radiopharmaceutical chemistry are being introduced. The radiotracers developed in China include: (1) Brain perfusion imaging agents and CNS radiotracers for -amyloid plaques, 1 receptors, and dopamine D 2 or D 4 receptors;(2) 99m Tc-and 18 F-labeled myocardial perfusion imaging agents; (3) tumor imaging agents including integrin-targeting radiotracer, novel sentinel lymph node imaging agents, hypoxia imaging agents, 99m Tc-labeled glucose derivatives, 2 receptor imaging agents, folate receptor imaging agents, and potential radiotracers for imaging of human telomerase reverse transcriptase expression; (4) Potential infection imaging agents; (5) Potential asialoglycoprotein receptor imaging agents; (6) Other imaging agents. Moreover, some prospects of research and development of radiopharmaceuticals in the near future are discussed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.